Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
THX-B (10 μM, 4 days) inhibits myoblast proliferation[1]. In C2C12 myoblasts, THX-B (10 μM, 1 h) suppresses the phosphorylation of ERK1/2 produced by NGF[1]. In cultured rd10 retinas, THX-B (20 μM, 24 h) reduces reactive gliosis and photoreceptor cell death[2].
|
---|---|
ln Vivo |
In a diabetic voiding dysfunction animal model, THX-B (50 μg in 125 μL PBS, ip weekly for 4 weeks) improves bladder function[3]. Photoreceptor cells in P17 rd10 mice exhibit a neuroprotective response to THX-B (2 μL of 2 μg/μL, IVT injection, single dose)[2]. The retinal pathology's inflammatory, vascular, and neurodegenerative phases are resolved with THX-B (40 μg in 20 μL, IVT injection)[4].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: C2C12 myoblasts Tested Concentrations: 10 μM Incubation Duration:Pre-treated for 1 hour Experimental Results: Inhibited βNGF-induced ERK2 phosphorylation by 67%. Inhibited proNGF-induced ERK2 phosphorylation by 90%. Immunofluorescence[1] Cell Types: Cultured P22 rd10 retinas. Tested Concentrations: 20 μM Incubation Duration: 24 h Experimental Results: Attenuated the thickening and enlargement of processes of astrocytes and Müller glia cells. |
Animal Protocol |
Animal/Disease Models: Mouse model of diabetic voiding dysfunction
Doses: 50 μg in 125 μL PBS Route of Administration: intraperitoneal (ip) injection Experimental Results: Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14% , 60%) lower after 2 and 4 weeks of treatment. Animal/Disease Models: P17 rd10 mice[1] Doses: 2 μL of 2 μg/μL, single dose Route of Administration: Intravitreal (IVT) injected in one eye Experimental Results: Increased the number of photoreceptor rows as well as the ONL/INL ratio. diminished the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα. |
References |
[1]. Keren Ettinger, et al. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cell Signal. 2012 Dec;24(12):2378-88.
[2]. María Platón-Corchado, et al. p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death Dis. 2017 Jul 13;8(7):e2922. [3]. Abubakr H Mossa, et al. Antagonism of proNGF or its receptor p75 NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia. 2020 Sep;63(9):1932-1946. [4]. Alba Galan, et al. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2852-2862. |
Molecular Formula |
C16H24N6O4
|
---|---|
Molecular Weight |
364.40
|
CAS # |
1372206-64-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CN1C(=O)C2N(CC(N(C(C)C)C(NC(C)C)=O)=O)C=NC=2N(C)C1=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (274.42 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7442 mL | 13.7212 mL | 27.4424 mL | |
5 mM | 0.5488 mL | 2.7442 mL | 5.4885 mL | |
10 mM | 0.2744 mL | 1.3721 mL | 2.7442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.